Twist Bioscience expands Alliance Panel

By The Science Advisory Board staff writers

October 6, 2021 -- Twist Bioscience has expanded its Alliance Panel offering to include products designed by expert collaborators that have a wide range of clinical applications.

In exchange for their participation, expert collaborators will receive a royalty on product sales and will carry partner branding, the company said. Twist's new Twist Alliance Pan-Cancer Methylation Panel is based on the Cancer Genome Atlas (TCGA) database, which includes 31 cancer types and 47 TCGA database disease entities.

In validation studies using tumor biopsy samples, DNA methylation regions included in the panel differentiated cancer tissues from nonmalignant tissue in breast, colorectal, and non-small cell lung cancers, according to Twist.

Twist, DeepCDR collaborate on antibody libraries
Twist Bioscience announced it is collaborating with DeepCDR to apply deep-learning algorithms to Twist's antibody discovery and optimization capabilities.
Twist inks collaboration deal with Adicet Bio
Twist Bioscience and Adicet Bio will collaborate on the discovery and development of gamma delta T-cell cancer therapies.
Boehringer, Twist to collaborate on antibody discovery
Boehringer Ingelheim and Twist Bioscience have entered a research collaboration to discover therapeutic antibodies against multiple targets.
Twist reports revenue increases for Q3
Twist Bioscience reported revenue increases for the third quarter of fiscal 2021, which ended June 30.
Twist incorporates Molcure AI into antibody discovery efforts
Twist Bioscience announced that it has used Molcure's artificial intelligence (AI) technology to generate new cancer antibodies.

Copyright © 2021 scienceboard.net


Conferences
Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter